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therapeutics. We have attempted to deﬁne elements of a hemato-
poietic stem cell niche by focusing on the endosteal surface where
some stem cells are known to localize in the adult mammal. Using
genetic models altering features of the bone or the stem cell
response to bone elements, we and others have begun to charac-
terize components of the endosteal stem cell niche. The molecular
interactions governing the effects of the niche provide potential
targets for drug based therapies and some of these can simply
re-purpose existing compounds. Using PTH analogues developed
for osteoporosis for example has been shown to alter the outcome
of both stem cell harvesting and engraftment procedures in the
mouse model. The application of these models to human trials has
begun. Targeting the niche may modify the complex systems in
which stem cells reside and provides a distinct therapeutic ap-
proach to stem cell based medicine.
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MANAGEMENT OF PRIMARY GRAFT FAILURE AFTER UNRELATED UM-
BILICAL CORD BLOOD TRANSPLANTATION
Ka Wah Chan, Michael S. Grimley, Candace Taylor, Donna A. Wall
Division of Pediatric Stem Cell Transplantation, Texas Transplant
Institute and Methodist Children’s Hospital, San Antonio, Texas
Primary graft failure (GF) is a major risk in unrelated donor
umbilical cord blood transplant (UCBT). We retrospectively re-
viewed data from 100 consecutive patients transplanted at Texas
transplant Institute between 3/2001 and 8/2006, and analyzed the
risk factors and the management of this complication. Their me-
dian age was 5.3 (range 0.1-8.4) years, and median weight 22 (range
4-85) kg. Seventeen did not achieve myeloid recovery; deﬁned as
an absolute neutrophil count (ANC)  500/	l by day 28. Of these,
8 died early from transplant-related complications or persistent
leukemia. Nine patients received 2nd UCBT in 33 to 95 (median
55) days. Their diagnoses were: ALL (3), MDS (1), HLH (2), SAA
(1), CD40L deﬁciency (1). Intensive immunosuppression condi-
tioning was used: the commonest regimen being ﬂudarabine
175mg/m2, cyclophosphamide 50mg/kg, TBI 2 Gy, 
 ATG (6
patients). Median cell dose for 2nd UCBT was 7.8  107/kg.
Degree of HLA matching was similar to 1st UCBT. 8/9 evaluable
patients engrafted; ANC 500/	l at a median of 15 (range 5-64)
days, platelets  20,000 /	l at a median of 92 (range 24 to 137)
days after the 2nd UCBT. All achieved complete donor chimerism.
As of 2/28/2007, 5/9 patients are alive, 758-1,828 (median 1,224)
days after 2nd UCBT. EBV-lymphoproliferatve disorders devel-
oped in 2 patients. Late infections were common: viral infections
included: BKV(2), HHV-6(2), CMV (2); and adenovirus (1). These
were severe and protracted. Acute graft-versus-host disease
(GVHD) diagnosed in 3/ 8, and chronic GVHD in 6/8 patients.
Three patients remain on immunosuppressive therapy. Chimerism
study by PCR was predictive of subsequent engraftment: any result
showing  5% donor cells was associated with irreversible graft
loss. In conclusion, early 2nd UCBT is a feasible treatment for
primary GF. Using an immunosuppressive preparative regimen
lead to reliable engraftment, but the incidence of chronic GVHD
and viral reactivation were high.
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DIRECT INTRA BONE TRANSPLANT OF UNRELATED CORD BLOOD
CELLS IS ASSOCIATED WITH FAST AND COMPLETE HEMATOLOGIC
RECOVERY
A. Ibatici, A.M. Raiola, F. Gualandi, N. Sessarego, A. Parodi, S. Pozzi,
M. Gobbi, M. Corselli, M. Podesta`, G. Piaggio, A. Bacigalupo and F.
Frassoni Centro Cellule Staminali e Terapia Cellulare, Divisione Ema-
tologia, Clinica Ematologia, Ospedale San Martino, Genova, Italy
Background. Cord blood transplants (CBT) are associated with
delayed or failed engraftment in a signiﬁcant proportion of pa-
tients. Two of our previous observations suggested (i) that, in the
animal model, direct intra-bone (i.b.) injection of hematopoietic
cells improves seeding efﬁciency and (ii) that the delayed engraft-
ment was not related to an insufﬁcient number of hematopoietic
stem cells but rather to a reluctance to differentiation and matu-
ration. Methods. Unrelated CB (4/6 or 5/6 HLA antigen matched)
were selected for 20 consecutive patients. Median cell dose was
2.6  10∧7/kg (range 1.6-3.5). CB cells were concentrated in a
total volume of 20 ml and infused in the supero-posterior iliac crest
(SPIC) under rapid general anesthesia (10 minutes with propofol).
Patients median age was 38 years (18-63), 16 had acute leukemia,
2 chronic myeloid leukemia, 2 Hodgkin disease. Sixteen patients
had refractory or advanced disease, whereas 4 had high risk ﬁrst
remission leukemia. Most patients (n16) were prepared with
conventional CY-TBI. Results. The infusion of cells i.b. in supero-
posterior iliac rest (SPIC), in the operating room, under short
general anaesthesia, was uneventful. All patients engrafted. Cumu-
lative incidence of neutrophil and platelet engraftment was 100%
at 50 days. Median for neutrophil engraftment (0.510∧9/l) was
day 23 (14-40), whereas for platelets (2010∧9/l) it was day 38
(range 22-47). Three patients are not evaluable because they died
within day 10 from transplant. Two patients relapsed and two died
of infection and multiorgan failure. Twelve patients are alive and
well in hematologic remission at a median follow up of 6 months
(range 2-11). 100% donor chimerism was documented since 30
days onward after transplant, including those in which CB cells
were injected monolaterally in one SPIC. From day60, CFC and
LTC-IC had already reached the lower values of the range of
normal individuals in bilateral sites. This is particularly relevant
considering that hemopoietic progenitor reconstitution remains
deﬁcient years after allo-transplant. Thus, direct injection of CB
cells in the bone marrow spaces produces in situ proliferation and
maturation, rapid recovery of peripheral blood counts, and early
recirculation of stem cells to other un-injected bone marrow sites.
Acute GvHD grade II was seen in 2/20 patient (10%). Since
lymphocyte trafﬁcking is known to be an essential part of immune
response, two combined factors might contribute: (i) injected T
cells come immediately in direct contact with mesenchymal stem
cells (MSC) and osteoblasts which are known to be potent immu-
nomodulators; (ii) the T cells present in the graft do not reach
primarily in the lymphatic organs, where they would be immedi-
ately confronted with host antigen presenting cells, as it probably
occurs after intra-venous injection. Conclusion. This study shows
that CB cells injected directly into the iliac crests are associated
with fast and complete hematologic recovery and almost absent
acute GvHD. The direct intra-bone transplant of CB cells could
now be offered to many more adult patients. This may change our
policy of hemopoietic cell transplants.
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A “NO-WASH” ALBUMIN-DEXTRAN DILUTION STRATEGY FOR UMBIL-
ICAL CORD BLOOD (UCB) THAW FOR ADOLESCENT AND ADULT UCB
TRANSPLANT RECIPIENTS: SUPERIOR TO WASH?
Juliet N. Barker, Rebecca Hawke, Allison Schaible, Michelle Abboud,
Nancy H. Collins, and Andromachi Scaradavou
The albumin-dextran wash, appropriate for small children, has
been adopted for adult UCB transplant (UCBT) recipients as a
matter of convention. However, an alternative strategy dilutes the
product in albumin-dextran without centrifugation. This “no
wash” technique could be advantageous for adolescents and adults
in whom even small cell losses may be clinically signiﬁcant, and
who are likely to tolerate small amounts of DMSO. Further, unlike
a bedside thaw, albumin-dextran dilution is still conducted in the
controlled environment of the Cytotherapy Laboratory. There-
fore, we conducted a prospective study of albumin-dextran dilution
in clinical UCBT. UCBT recipients  40 kg were eligible. Our
hypothesis was that the “no wash” thaw will be comparable to wash
in terms of post-thaw TNC yield and engraftment. To date, 37
units have been thawed using albumin-dextran dilution and trans-
planted into 19 patients (all received double unit grafts 4-6/6 HLA
matched, one red cell containing unit was washed). All patients
(median age 36 years, range 10-65 years; median weight 77 kg,
range 49-111) had hematological malignancies. A 5:1 Gen-
tran®40/ 25% albumin solution was used. Red cell depleted units
(n 35) were thawed to a dilution 5.5 fold [median ﬁnal volume
200 mls (range 200-500mls)]. The larger volume red cell contain-
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ing units (n 2) were diluted at least 4 fold to a ﬁnal volume of 400
mls. The median infused TNC was 2.13 x 107/kg with a TNC
recovery of 85% (range 50-105%) and a median trypan blue via-
bility of 89% (range 59-95%). While 6 patients had hypertension,
3 nausea and 1 chest tightness requiring intravenous therapy, no
patient suffered any severe adverse events associated with infusion.
The cumulative incidence of sustained donor neutrophil engraft-
ment was 100% in recipients of ablative regimens at a median of 26
days (range 14-33), and 89% in non-myeloablative recipients with
neutrophil recovery occurring at a median of 16 days (range 7-36).
The cumulative incidence of grades II-IV acute GVHD was 42%
at 100 days with no cases of grade IV acute GVHD, and 20% of
patients have chronic GVHD to date. In summary, we conclude
that this thaw technique is a valid alternative to UCB wash in adults
and larger children with cell dose yield and engraftment that
compare favorably to a traditional wash. This technique is faster,
more efﬁcient, reduces unit manipulation, speeds the time to pa-
tient infusion, and reduces the potential for loss of cells and may
therefore be the thaw technique of choice for adult UCBT.
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NONMYELOABLATIVE STEM CELL TRANSPLANTATION
Richard Champlin, M.D. MD Anderson Cancer Center
High dose myeloablative therapy with allogeneic hematopoietic
transplantation is an effective, yet risky treatment for hematologic
malignancies. There is a high risk of treatment related complica-
tions, ranging from 10 to 50% depending on histocompatibility,
age comorbidities and disease factors. The initial concept of allo-
geneic transplantation for treatment of cancer was to use the
transplant for supportive care, as a means to restore hematopoiesis
after myeloablative doses of chemotherapy and/or total body radi-
ation. The therapeutic beneﬁt of allogeneic marrow transplanta-
tion for many diagnoses is largely related to an associated immune-
mediated graft-vs.-malignancy effect. This realization has recently
led to development of less toxic, nonmyeloablative preparative
regimens to achieve engraftment and allow development of graft-
vs.-malignancy effects as a primary form of therapy. Engraftment is
favored by a high CD34 cell dose and histocompatiblity between
donor and recipient. More intensive immunosuppression is re-
quired to prevent rejection with greater genetic disparity. For cord
blood transplants, the preparative regimen must be sufﬁciently
immunosuppressive to prevent rejection of the cord blood graft,
involving a low cell dose and usually multiple HLA mismatches.
For nonmalignant disorders, it is not necessary to ablate diseased
tissues; it is only necessary to achieve mixed chimerism to provide
a source of normal hematopoietic cells. Results of nonablative stem
transplants will be reviewed for each hematologic malignancy. In
many diagnoses, it still appears necessary to induce marked cytore-
duction by the preparative regimen to achieve optimal results.
Strategies to augment graft-vs-malignancy immune effects are be-
ing studied to reduce the risk of disease relapse. Novel strategies
are under evaluation for separation of graft-vs-malignancy from
GVHD. Overall this strategy has been successful in reducing the
risks of treatment related mortality and making it a potentially
curative treatment option to older patients and those with comor-
bidities who where previously not eligible for allogeneic stem cell
transplantation.
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NONMYELOABLATIVE UMBILICAL CORD BLOOD TRANSPLANTATION
Claudio G. Brunstein, Todd DeFor and John E. Wagner Bone &
Marrow Transplant Program University of Minnesota
Over the last 20 years, umbilical cord blood(UCB) has become an
increasingly used source of hematopoeitic stem cells for transplan-
tation. For pediatric patients, UCB is now routinely utilized as a
source of stem cells. However, the median age of presentation of
most hematologic malignancies is in the 5th and 6th decades of life,
a time when other co-morbidities are more likely. Also, patients are
frequently referred to transplantation after extensive prior therapy,
including prior autologous transplantation. Nonmyeloablative
transplantation is particularly suitable for older patients and those
with other signiﬁcant clinical problems. The nonmyeloablative
conditioning regimens utilize drugs that are potently immunosup-
pressive with less toxicity and shortened periods of neutropenia.
The utilization of UCB as a source of stem cells for non myeloa-
blative transplantation was based on the hypothesis that despite less
alloreactivity, UCB would have enough T cells to mediate engraft-
ment. Several groups have now reported results with nonmyeloa-
blative UCB transplantation. The conditioning regimen has varied
signiﬁcantly; however, most institutions have included ﬂudarabine
and TBI. Among the series reported the median age of patients at
transplantation has ranged from 47 to 59 years, and the median
time to neutrophil recovery ranged between 12 and 21 days, with
an incidence of graft failure between 13% to 16%. The variation
on the time to neutrophil recovery largely reﬂects differences in
the intensity of the conditioning regimen. Despite the fact that the
best nonmyeloablative conditioning regimen for UCB transplan-
tation is not yet established, a recent study by Rocha et al. suggests
the combination of cyclophosphamide, ﬂudarabine and total body
irradiation may be superior to other regimens, with an incidence of
sustained donor engraftment of approximately 90%, as compared
to 65% with other regimens. The reported incidences of acute
graft-versus-host disease have ranged between 21% and 63%, and
chronic graft-versus-host disease 12% and 50%. Treatment related
mortality has been remarkably low, ranging from 18% to 27%.
Overall survival has been 33% to 44%. The University of Minne-
sota has the largest single center experience with nonmyeloabla-
tive UCB transplantation. The Minneapolis conditioning regi-
men consists of cyclophosphamide 50mg/kg, ﬂudarabine
200mg/m2 and a single dose of TBI 200cGy. The posttrans-
plantation immunosuppression is cyclosporine A and mycophe-
nolate mofetil. For patients who have not received intensive
chemotherapy in the 3 months prior to transplantation, anti-
thymocyte globulin was added to the conditioing regimen. If a
single unit is not large enough to be used as a graft, patients are
eligible to receive two partially HLA matched UCB units. UCB
unit grafts are at least 4/6 HLA matched to the recipent (HLA-A
and B at the antigen level, and DRBI at the allele level). In the
case of double unit grafts, units are at least 4/6 HLA matched to
the recipient and to each other, not necessarily at the same loci.
The median infused nucleated cell dose is 3.3  107/kg recip-
ients of one unit, compared to 3.7  107/kg for recipients of two
units. With 161 patients, primary neutrophil recovery is ob-
served in 94% with sustained donor engraftment in 87%. There
is no signiﬁcant difference between recipients of one or two
UCB units. Treatment related mortality is 25% at 3 years. The
incidence of Grade II-graft-versus-host disease is 54% and
grade III-IV 18%. Progression-free survival is 38% at 5 years
with a trend towards better progression-free survival for recip-
ients of 2 UCB units. Overall survival is 45% at 5 years, with no
signiﬁcant difference for recipients of one or two UCB units. In
multivariate analysis, disease’s status at transplantation and the
presence of clinical high-risk features were the two factors
correlated with higher risk of treatment related mortality,
poorer event-free survival and overall survival. In conclusion, a
growing body of evidence suggests that UCB is a safe and
efﬁcacious source of stem cells in the setting of myeloablative
transplantation. Patients who need non myeloabalative trans-
plant and who do not have a suitable sibling or unrelated donor
should be considered for UCB transplantation. Larger numbers
of patients will help further determine the role of UCB trans-
plantation in older patients and those with pre-exising co-
morbidities.
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DOUBLE REDUCED INTENSITY CORD BLOOD TRANSPLANTS IN ADULTS
Karen K. Ballen, Corey Cutler, Beow Y. Yeap, Steven L. McAfee,
Bimalangshu R. Dey, Eyal C. Attar, Richard L. Haspel, Deborah Liney,
John Koreth, Vincent Ho, Edwin P. Alyea, Robert J. Soiffer, Thomas R.
Spitzer, and Joseph H. Antin Massachusetts General Hospital and Dana
Farber Cancer Institute, Boston, MA
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